Globus Medical PE Ratio 2010-2022 | GMED

Current and historical p/e ratio for Globus Medical (GMED) from 2010 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Globus Medical PE ratio as of September 23, 2022 is 29.59.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Globus Medical PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2022-09-23 58.29 39.12
2022-06-30 56.14 $1.49 37.68
2022-03-31 73.78 $1.36 54.25
2021-12-31 72.20 $1.43 50.49
2021-09-30 76.62 $1.81 42.33
2021-06-30 77.53 $1.80 43.07
2021-03-31 61.67 $1.19 51.82
2020-12-31 65.22 $1.00 65.22
2020-09-30 49.52 $0.92 53.83
2020-06-30 47.71 $0.86 55.48
2020-03-31 42.53 $1.45 29.33
2019-12-31 58.88 $1.53 38.48
2019-09-30 51.12 $1.45 35.26
2019-06-30 42.30 $1.42 29.79
2019-03-31 49.41 $1.48 33.39
2018-12-31 43.28 $1.40 30.91
2018-09-30 56.76 $1.30 43.66
2018-06-30 50.46 $1.24 40.69
2017-12-31 41.10 $1.10 37.36
2017-09-30 29.72 $1.10 27.02
2017-06-30 33.15 $1.23 26.95
2017-03-31 29.62 $1.21 24.48
2016-12-31 24.81 $1.18 21.03
2018-03-31 49.82 $1.22 40.84
2016-09-30 22.57 $1.22 18.50
2016-06-30 23.83 $1.23 19.37
2016-03-31 23.75 $1.21 19.63
2015-12-31 27.82 $1.18 23.58
2015-09-30 20.66 $1.08 19.13
2015-06-30 25.67 $1.04 24.68
2015-03-31 25.24 $1.01 24.99
2014-12-31 23.77 $0.97 24.51
2014-09-30 19.67 $0.90 21.86
2014-06-30 23.92 $0.88 27.18
2014-03-31 26.59 $0.74 35.93
2013-12-31 20.18 $0.73 27.64
2013-09-30 17.46 $0.73 23.92
2013-06-30 16.86 $0.69 24.43
Sector Industry Market Cap Revenue
Medical Medical Instruments Manufacturing $5.801B $0.958B
Globus Medical, Inc. is a medical device company that develops and commercializes healthcare solutions for patients with musculoskeletal disorders. The company currently has its sales operations distributed across counties world wide. Its Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, and unique surgical instruments, used in an expansive range of spinal, orthopedic and neurosurgical procedures. The spine products address the vast majority of conditions affecting the spine including degenerative conditions, deformity, tumors and trauma. Enabling Technologies are designed to enhance a surgeon's capabilities and streamline the complicated surgical procedures to be safer, less invasive, accurate and more reproducible to improve patient care and reduce radiation exposure for both patient and caregiver. The technology contains imaging, navigation and robotic assisted surgery solutions. It acquired all assets of StelKast, Inc. and Finnish engineering company Synoste Oy.
Stock Name Country Market Cap PE Ratio
Thermo Fisher Scientific (TMO) United States $204.040B 20.78
Edwards Lifesciences (EW) United States $52.534B 37.17
Alcon (ALC) Switzerland $29.415B 24.91
STERIS (STE) Ireland $16.731B 20.78
Teleflex (TFX) United States $9.732B 15.51
Fresenius Medical Care AG KGaA (FMS) Germany $8.433B 7.78
Penumbra (PEN) United States $7.007B 840.64
Glaukos (GKOS) United States $2.385B 0.00
Integer Holdings (ITGR) United States $2.051B 16.04
Nevro (NVRO) United States $1.548B 0.00
Paragon 28 (FNA) United States $1.343B 0.00
AVANOS MEDICAL, INC (AVNS) United States $1.035B 15.85
Artivion (AORT) United States $0.537B 51.19